Journal of microbiology, immunology, and infection = Wei mian yu gan ran za zhi · 2026
Clinical outcomes in patients hospitalized for COVID-19 in the periods of non-Omicron and Omicron variant dominance.
СтатьяНазвание и аннотация: Перевод в очереди
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Hsieh Yi-Jhen, Wu Bing-Chen, Huang Shih-Wei, Hsu Chen-Chuan, Cheng Hsin-I, Chang Ko-Wei, Huang Allen Chung-Cheng, Lin Chang-Wei, Lin Ting-Yu, Lin Horng-Chyuan, Chiu Cheng-Hsun, Lin Shu-Min
Аннотация
BACKGROUND: Omicron is known for its higher transmissibility and milder respiratory symptoms than those of other SARS-CoV-2 variants. How comorbidities contribute to mortality outcomes in Omicron-related COVID-19 remains unclear. This study compared clinical features and outcomes between Omicron and non-Omicron variants and identified risk factors for in-hospital mortality.
METHODS: This retrospective cohort study was conducted from April 2020 to September 2022. Patients with COVID-19 infection were divided into Omicron and non-Omicron groups. Demographic data, laboratory results, and treatment information were collected and analyzed. Clinical outcomes for different variants were analyzed.
RESULTS: The Omicron group had a greater burden of comorbidities but exhibited lower COVID-19 disease severity and fewer complications than did the non-Omicron group. Overall mortality was relatively high in the Omicron group, primarily due to non-COVID-related causes. In multivariate analysis, a Charlson comorbidity index score of ≥3 (odds ratio [OR] = 4.60, 95% confidence interval [CI] = 1.94-10.91, p < 0.001), severe or critical COVID-19 (OR = 1.60, 95% CI = 1.24-2.07, p < 0.001), a high white blood cell count (OR = 1.00, 95% CI = 1.00-1.00, p = 0.021), and a high C-reactive protein level (OR = 1.01, 95% CI = 1.00-1.01, p = 0.003) emerged as positive predictors of COVID-19-related mortality.
CONCLUSION: Severe or critical COVID-19 and a Charlson comorbidity index score of ≥3 were independently associated with high in-hospital mortality. Intensive monitoring and early intervention should be prioritized for high-risk groups to improve clinical outcomes.
METHODS: This retrospective cohort study was conducted from April 2020 to September 2022. Patients with COVID-19 infection were divided into Omicron and non-Omicron groups. Demographic data, laboratory results, and treatment information were collected and analyzed. Clinical outcomes for different variants were analyzed.
RESULTS: The Omicron group had a greater burden of comorbidities but exhibited lower COVID-19 disease severity and fewer complications than did the non-Omicron group. Overall mortality was relatively high in the Omicron group, primarily due to non-COVID-related causes. In multivariate analysis, a Charlson comorbidity index score of ≥3 (odds ratio [OR] = 4.60, 95% confidence interval [CI] = 1.94-10.91, p < 0.001), severe or critical COVID-19 (OR = 1.60, 95% CI = 1.24-2.07, p < 0.001), a high white blood cell count (OR = 1.00, 95% CI = 1.00-1.00, p = 0.021), and a high C-reactive protein level (OR = 1.01, 95% CI = 1.00-1.01, p = 0.003) emerged as positive predictors of COVID-19-related mortality.
CONCLUSION: Severe or critical COVID-19 and a Charlson comorbidity index score of ≥3 were independently associated with high in-hospital mortality. Intensive monitoring and early intervention should be prioritized for high-risk groups to improve clinical outcomes.